Therapy Areas: AIDS & HIV
AIDS Healthcare Foundation calls on Gilead Sciences for USD10bn victim compensation fund
19 July 2019 - United States-based AIDS Healthcare Foundation (AHF) is calling on Gilead Sciences Inc, a United States-based biotechnology company, to establish a USD10bn victim compensation fund, it ...
Lyndra Therapeutics and Gilead Sciences to Collaborate on Development of Ultra-Long-Acting HIV Therapeutics
12 July 2019 - - US-based sustained-release therapies developer Lyndra Therapeutics has forged a partnership with US-based biopharmaceutical company Gilead Sciences, Inc. (NASDAQ: GILD) to develop and...
ViiV Healthcare, Pfizer and Shionogi reveal positive Week 48 results from phase III TANGO study of dolutegravir plus lamivudine
12 July 2019 - ViiV Healthcare, a global specialist HIV company majority-owned by GSK, in collaboration with United States-based Pfizer Inc and Japan-based Shionogi Limited as shareholders have reveal...
ViiV Healthcare commences trial to identify and evaluate approaches for implementation of once-monthly HIV treatment
10 July 2019 - United Kingdom-based ViiV Healthcare has started a trial to identify and evaluate approaches for implementing its once-monthly injectable treatment for HIV into clinical practice, it wa...
Lyndra Therapeutics collaborates with Gilead Sciences
10 July 2019 - United States-based Lyndra Therapeutics has collaborated with United States-based Gilead Sciences Inc to develop and commercialise ultra-long-acting oral HIV therapies, it was reported ...
European Commission grants marketing authorisation to ViiV Healthcare's Dovato
5 July 2019 - The European Commission has granted marketing authorisation to United Kingdom-based ViiV Healthcare for its Dovato (dolutegravir/lamivudine) that is intended to treat HIV-1 infection, it...